Moderna's injection, mRNA-1273 is co-owned with the US Government, as the company has been funded by the defense research grants for years and also received intellectual property transfers from the US Government, in addition to preclinical and clinical research work conducted for Moderna by the NIH Vaccine Research Center.
The scope of the contract is "Manufacturing of up to 500M doses".
Further, in Amendment 1 the contract states: "cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA." Therefore, if FDA decides that no cGMP is necessary, then it's not necessary.
Under "Regulatory" the only thing that's defined is that Moderna is the sponsor of the product, IND and BLA. Then it says that the DOD will use this law for the product: "DoD Medical Product Priority. PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel. The contractor recognizes that only the DoD can utilize PL 115-92.".
Clearly, the US military invokes pub law 115-92 in their multi-billion contract w/Pfizer to produce a biowepon.
Add a Health Resources Priorities and Allocations System priority rating of DO-HR to this contract.
Add a Defense Priorities and Allocation System priority rating of DO-C9 to this contract to act as the equivalent to the HRPAS priority rating of DO-HR. Add FAR 52.211-15, Defense Priority and Allocation Requirements This is a rated order certified for national defense, emergency preparedness, and energy program use, and the Contractor shall follow all the requirements of the Defense Priorities and Allocations System regulation.
https://brownstone.org/articles/proof-vaccines-were-military-backed-countermeasure/
No comments:
Post a Comment